METTL3 Degrader

WD6305 TFA is a potent and selective METTL3-METTL14 PROTAC degrader. WD6305 TFA has DC₅₀ values of 140 nM and 194 nM for METTL3 and METTL14, respectively. WD6305 TFA inhibits m⁶A modification and proliferation of AML cells, and induces apoptosis. WD6305 TFA has antitumor activity.

WD6305 is a potent and selective METTL3-METTL14 PROTAC degrader. WD6305 has DC₅₀ values of 140 nM and 194 nM for METTL3 and METTL14, respectively. WD6305 inhibits m⁶A modification and proliferation of AML cells, and induces apoptosis.

AF151 is a METTL3 PROTAC degrader with the DC₅₀ of 0.43 μM in MOLM-13 cells. AF151 inhibits cell growth by significantly degrading METTL3 protein and reducing m6A levels. AF151 can induce cell apoptosis and reduce the level of Bcl-2 protein. AF151 can be used for research on cancer such as acute myeloid leukemia (AML). (Pink: METTL3 Ligand (HY-174874); Blue: VHL Ligand (HY-125845); Black: Linker; VHL Ligand+Linker (HY-174875)).

PROTAC METTL3 degrader 1 is a VHL-based PROTAC METTL3 degrader (DC₅₀: 220 nM in MOLM-13 cells). PROTAC METTL3 degrader 1 inhibits METTL3/14 complex with an IC₅₀ value of 341 nM. PROTAC METTL3 degrader 1 can be used for the research of acute myeloid leukemia and gastric cancer.

PROTAC METTL3-14 degrader 1 is a METTL3-METTL14 heterodimer complex PROTAC degrader. PROTAC METTL3-14 degrader 1 binds to the E3 ubiquitin ligase CRBN, forms a ternary complex with METTL3-METTL14, and promotes the ubiquitination and degradation of METTL3. PROTAC METTL3-14 degrader 1 is applicable to the research of acute myeloid leukemia and prostate cancer.